Clinical trials: Patients With Cancer
AL Amyloidosis
Daratumumab for the Treatment of Patients With AL Amyloidosis
Participants with AL Amyloidosis will receive the drug daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month.
- Trial name
- NCT02841033
- Testing
- daratumumab
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Boston Medical Center
Gastric Cancer
Response Rate and Side Effects of Preoperative Chemotherapy (TOX Regimen) in Patients With Locally Advanced Operable Gastric Adenocarcinoma
Early stage diagnosis of gastric cancer has ensued different approaches in its resection strategies. In order to increase the proportion of cases that undergo radical resection and reduce the recurrence rate, different…
- Trial name
- TOX (NCT01672333)
- Testing
- TOX
- Where
- Iran
- Volunteers
- 50 people
- Sponsor
- Milad Hospital
Neoplasms
A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)
This study has 2 parts. The first part of the study is done. The first part was open to adults with different types of advanced cancer (solid tumors).
- Trial name
- NCT03964233
- Testing
- BI 907828, ezabenlimab, BI 754111
- Where
- 23 sites in United States, Australia and 9 more
- Volunteers
- 119 people
- Sponsor
- Boehringer Ingelheim
Sleep Disorder, Stage IA Breast Cancer
Brief Behavioral Therapy in Improving Sleep Disorders in Patients With Stage I-III Breast Cancer Undergoing Chemotherapy
This randomized phase II trial studies how well brief behavioral therapy works in improving sleep disorders in patients with stage I-III breast cancer undergoing chemotherapy.
- Conditions
- Sleep Disorder, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT02002533
- Testing
- Brief Behavioral Therapy, Telephone-Based Intervention, Educational Intervention
- Where
- 6 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gary Morrow
Malignant Mesothelioma
Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT00004033
- Testing
- liposomal NDDP, therapeutic thoracoscopy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
This phase II MATCH treatment trial tests how well larotrectinib (LOXO-101) works in treating patients with cancer that has certain genetic changes.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm
- Trial name
- NCT06390852
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia
Treatment With Low-Dose Cytarabine in Elderly Patients (Age 70 Years or Older) With Acute Myeloid Leukemia: A Single Institution Experience.
The treatment of very elderly patients (≥70 years) with acute myeloid leukemia remains controversial. Although the outcome in younger adults has improved because of cytarabine- and anthracycline-based chemotherapy with advanced…
- Trial name
- NCT03350152
- Where
- France
- Volunteers
- 302 people
- Sponsor
- Hospices Civils de Lyon
Breast Cancer, Lung Cancer
Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning
The goal of this clinical trial is to explore feasibility, acceptability, and effectiveness of end-of-life conversation game "Hello" as a tool to help individuals with breast, lung, and/or genito-urinary cancers treated at Penn…
- Conditions
- Breast Cancer, Lung Cancer, Genito Urinary Cancer
- Trial name
- NCT06028152
- Testing
- End-of-life conversation game called "Hello"
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Milton S. Hershey Medical Center
Pneumonia, Interstitial, Cancer Patients
Study of of Oxygen Nebulized Inhalation EGCG in Cancer Patients With New Coronary Pneumonia
Epigallocatechin-3-gallate (EGCG) is a major polyphenol of green tea that possesses a wide variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous, and metabolic effects via modulation of a…
- Trial name
- NCT06924749
- Testing
- EGCG
- Where
- 2 sites in China
- Volunteers
- 111 people
- Sponsor
- Shandong Cancer Hospital and Institute
MSI-H, PD-1 Immunotherapy
PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery
Approximately 5% to 10% of gastric cancers have MSI-H/dMMR. According to the results of retrospective analysis of CLASSIC and MAGIC, MSI-H/dMMR was a good prognosis and potential negative predictor of adjuvant chemotherapy for…
- Conditions
- MSI-H, PD-1 Immunotherapy, Gastric Cancer, Adjuvant Therapy
- Trial name
- NCT05468138
- Testing
- SOX, XELOX, PD-1 antibody
- Where
- China
- Volunteers
- 94 people
- Sponsor
- Fudan University
Anaplastic Astrocytoma, Brain Stem Glioma
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
This phase I/II trial studies the side effects and the best dose of veliparib when given together with radiation therapy and temozolomide and to see how well they work in treating younger patients newly diagnosed with diffuse…
- Conditions
- Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma
- Trial name
- NCT01514201
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Investigators will conduct the trial to determine whether paclitaxel and cisplatin (PT) has the same curative effects and less adverse effects than bleomycin, etoposide and cisplatin(BEP) among newly diagnosed ovarian malignant…
- Conditions
- Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer
- Trial name
- SCST-01 (NCT02429700)
- Testing
- Paclitaxel, Carboplatin, Bleomycin
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Beihua Kong
Pancreatic Ductal Adenocarcinoma
NGS and TME for Evidence-based Treatment of Pancreatic Cancer
The tumor tissue of patients with pancreatic cancer will be submitted to next-generation sequencing (NGS) and these data will be evaluated with an oncology treatment decision support (TDS) software tool that is a medicinal…
- Trial name
- PePaCaKa-01 (NCT02767700)
- Testing
- NGS
- Volunteers
- 39 people
- Sponsor
- Karolinska University Hospital
Medullary Thyroid Cancer
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
- Trial name
- NCT05830500
- Testing
- Anlotinib Hydrochloride Capsule
- Where
- 19 sites in China
- Volunteers
- 360 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor
A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors
This study is an open exploratory clinical study to evaluate the safety, tolerance, immune response, and initial efficacy of autologous tumor infiltrating lymphocyte LM103 injection in advanced solid tumor patients .
- Trial name
- NCT05941936
- Testing
- LM103
- Where
- China
- Volunteers
- 5 people
- Sponsor
- Suzhou BlueHorse Therapeutics Co., Ltd.
Multiple Myeloma
A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma
The purpose of this post marketing study is to determine the plasma concentration of bortezomib (unchanged drug) to assess the pharmacokinetic (PK - the study of the way a drug enters and leaves the blood and tissues over time)…
- Trial name
- NCT01801436
- Testing
- Bortezomib
- Volunteers
- 14 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
This phase II MATCH treatment trial identifies the effects of copanlisib hydrochloride (copanlisib) in patients whose cancer has a genetic change called PIK3CA mutation.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Refractory Lymphoma
- Trial name
- NCT05490771
- Testing
- Biopsy Procedure, Computed Tomography, Copanlisib Hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Multiple Myeloma
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments)…
- Trial name
- NCT07226934
- Testing
- GPT-QPL
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Experimental Tumor
Chidamide for Patients With Recurrent and Metastatic Epstein-Barr Virus (EBV)-Associated Solid Tumors
Study of Chidamide as a Single-agent Treatment for Patients With Recurrent and Metastatic Epstein-Barr virus (EBV)-associated Solid Tumors
- Trial name
- NCT03494634
- Testing
- Chidamide
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Sun Yat-sen University
Neuroendocrine Tumors
Post-Authorization Long-Term Safety Study of LUTATHERA
Study to assess the long-term safety of LUTATHERA for the labeled indication (SmPC/USPI).
- Trial name
- SALUS (NCT03691064)
- Testing
- LUTATHERA
- Where
- 20 sites in United States, France and 3 more
- Volunteers
- 1,014 people
- Sponsor
- Advanced Accelerator Applications
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.